Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients.
Eklund
K K
KK
Remitz
A
A
Kautiainen
H
H
Reitamo
S
S
Leirisalo-Repo
M
M
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D008875:Middle Aged; D010865:Pilot Projects; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012720:Severity of Illness Index; D025241:Spondylarthritis / Q000188:drug therapy*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate